City Therapeutics, Inc. CTY
City Therapeutics, Inc. (Nasdaq: CTY) is a hematology drug developer. Its lead program, CITY-FXI, is in Phase 1 for thromboembolic disease (secondary stroke prevention, DOAC-ineligible AFib, VTE prophylaxis, cancer-associated thrombosis). Its next catalyst on record is CITY-FXI: Report additional Phase 1 data (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CITY-FXI — Report additional Phase 1 data (H2 2026). 9 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CITY-FXI | thromboembolic disease | RNA (siRNA/ASO/mRNA) | Phase 1 |
| CITY-RBP4 | Stargardt disease; GA | RNA (siRNA/ASO/mRNA) | Pre-clinical |
| CITY-TFR2 | anemia of chronic disease (myelofibrosis anemia) | RNA (siRNA/ASO/mRNA) | Pre-clinical |
| CITY-L04 | undisclosed | RNA (siRNA/ASO/mRNA) | Pre-clinical |
| CITY-O02 | ocular | RNA (siRNA/ASO/mRNA) | Pre-clinical |
| CITY-C02 | CNS | RNA (siRNA/ASO/mRNA) | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 hematology companies
- Damora Therapeutics, Inc. DMRA
- Omeros Corp OMER
- Rallybio Corp RLYB
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.